Renalytix PLC Change of Registered Address
05 April 2024 - 12:39PM
RNS Regulatory News
RNS Number : 5295J
Renalytix PLC
05 April 2024
Renalytix
plc
("Renalytix" or the "Company")
Change of Registered Address
LONDON and SALT LAKE
CITY, April 5, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE:
RENX), an artificial intelligence-enabled in vitro
diagnostics company, focused on optimising clinical management of
kidney disease to drive improved patient outcomes and advance
value-based care, announces that the
Company's registered address has changed to 2 Leman Street,
London, United Kingdom, E1W 9US.
For
further information, please contact:
Renalytix
plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook PR
|
|
|
Stifel (Nominated
Adviser, Joint Broker)
|
Tel: 020 7710 7600
|
Alex Price / Nicholas Moore / Nick Harland / Samira
Essebiyea
|
|
|
|
Investec Bank plc
(Joint Broker)
|
Tel: 020 7597 4000
|
Gary Clarence / Shalin Bhamra
|
|
|
|
Walbrook PR
Limited
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com
|
Paul McManus / Alice Woodings
|
Mob: 07980 541 893 / 07407
804 654
|
|
|
CapComm
Partners
|
|
Peter DeNardo
|
Tel: 415-389-6400 or investors@renalytix.com
|
|
| |
About
Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro
diagnostics and laboratory services company that is the global
founder and leader in the new field of bioprognosis™ for kidney
health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
CROUVORRSWUSRAR
Renalytix (LSE:RENX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Renalytix (LSE:RENX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024